GlassScriptPhysician profile
William L Riggs
NPI 1538193230
$9,868.73
in general payments reported to CMS, 2019-2025
27 companies · $2,264 in 2025
The $2,264 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $760 · 2021: $1,217 · 2022: $2,105 · 2023: $1,832 · 2024: $1,127 · 2025: $2,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,197 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,197.16 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $2,828.43 | 2019-2025 | Idosetr, Kxl System (Not Refurbished), Istent Inject Trabecular Micro-Bypass System |
| Bausch & Lomb Americas INC. | $1,426.12 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Alcon Vision LLC | $1,353.52 | 2019-2025 | Clareon, Acrysof Iq Vivity, Acrysof Iq Panoptix Uv Iol |
| Biotissue Holdings INC. | $898.40 | 2025 | |
| Ocular Therapeutix, INC. | $543.55 | 2020-2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $481.90 | 2019-2025 | Cequa |
| Rxsight INC | $472.64 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Abbvie INC. | $240.51 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Lensar, INC. | $215.89 | 2025 | Lensar Laser System |
| Shire North American Group INC | $174.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $172.61 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $145.62 | 2020-2022 | |
| Sight Sciences, INC. | $140.51 | 2022-2023 | Omni Surgical System |
| Dompe US, INC. | $111.18 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $99.12 | 2022-2025 | Tyrvaya, Ryzumvi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $93.90 | 2020-2021 | |
| Allergan, INC. | $85.20 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $75.46 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $69.34 | 2021 | |
| Horizon Therapeutics Plc | $46.60 | 2023 | Tepezza |
| Carl Zeiss Meditec, INC. | $39.07 | 2020 | |
| Amgen INC. | $35.60 | 2025 | Tepezza |
| Harrow Eye, LLC | $33.75 | 2025 | Triesence |
| Rayner Intraocular Lenses Limited | $31.43 | 2022 | |
| Omeros Corporation | $18.98 | 2019 | |
| New World Medical,INC. | $18.44 | 2025 | Via360, Clearpath, Streamline |
| Johnson & Johnson Surgical Vision, INC. | $15.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Riggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.